CarlaDKurkjianMD

Oncology • Oklahoma City, OK

Assistant Professor, Medicine, University of Oklahoma College of Medicine

Join to view full profile

Dr. Kurkjian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kurkjian's full profile

Already have an account?

Office
4401 Mcauley Blvd
Suite 2700
Oklahoma City, OK 73120
Phone+1 405-271-4022

Fax+1 405-271-3020
Is this information wrong?

Education & Training

University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Oklahoma College of MedicineClass of 2001

Certifications & Licensure

CA State Medical License 2009 - Present
TX State Medical License 2014 - 2025
OK State Medical License 2002 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer Start of enrollment: 2010 Nov 01
Terminated
Phase 1, Phase 2
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance Start of enrollment: 2011 Jan 01
Completed
Phase 3
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2011 Sep 19
Completed
Phase 1, Phase 2
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy Start of enrollment: 2011 Jul 01
Completed
Phase 2
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC Start of enrollment: 2013 Jun 19
Completed
Phase 1
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Start of enrollment: 2013 May 01
Terminated
Phase 2
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Start of enrollment: 2013 Sep 20
Active, not recruiting
Phase 2
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

53 citations
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Geoffrey I. Shapiro, Patricia LoRusso, E. L. Kwak, Susan Pandya, Charles M. Rudin, Carla Kurkjian, James M. Cleary, Mary Jo Pilat, Suzanne F. Jones, Alex de Crespigny,...> ;Investigational New Drugs. 2020 Apr 1
32 citations
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients...
Carol Aghajanian, Katherine M. Bell-McGuinn, Howard A. Burris, Lillian L. Siu, Lee Ann Stayner, Jennifer J. Wheler, David S. Hong, Carla Kurkjian, Shubham Pant, Ademi ...> ;Investigational New Drugs. 2018 Apr 3
7 citations
Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide
John J. Krais, Needa A. Virani, Partick H. McKernan, Quang Nguyen, Kar Ming Fung, Vassilios I. Sikavitsas, Carla Kurkjian, Roger G. Harrison> ;Molecular Cancer Therapeutics. 2017 Sep 1
4 citations
Impact of Health Care Insurance Status on Treatment Outcomes of Acute Myeloid Leukemia.
Samer A. Srour, Michael Machiorlatti, Namali Pierson, Usman Bhutta, Mohamad Cherry, George B. Selby, David M. Thompson, Sara K. Vesely, Carla Kurkjian> ;Clinical Lymphoma, Myeloma & Leukemia. 2017 Jul 1
24 citations
A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the ...
Shubham Pant, Manish Patel, Carla Kurkjian, Brian Hemphill, Maria Flores, D. S. Thompson, Johanna C. Bendell> ;Cancer Investigation. 2017 Jun 29
33 citations
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
Howard A. Burris, Carla Kurkjian, Lowell L. Hart, Shubham Pant, Patrick Murphy, Suzanne F. Jones, Rachel Neuwirth, Chirag Patel, F. Zohren, J. R. Infante> ;Cancer Chemotherapy and Pharmacology. 2017 Jun 10
56 citations
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer
Shubham Pant, Suzanne F. Jones, Carla Kurkjian, Jeffrey R. Infante, Kathleen N. Moore, Howard A. Burris, D.S. McMeekin, Karim A. Benhadji, Bharvin K. R. Patel, Martin ...> ;European Journal of Cancer. 2016 Mar 1
4 citations
Annexin V-directed enzyme prodrug therapy plus docetaxel for the targeted treatment of pancreatic cancer
Katrin P. Guillen, Antonietta Restuccia, Carla Kurkjian, Roger G. Harrison> ;Pancreas. 2015 Aug 1
26 citations
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors
Johanna C. Bendell, Manish R. Patel, Jeffrey R. Infante, Carla Kurkjian, Suzanne F. Jones, Shubham Pant, Howard A. Burris, Ofir Moreno, Vanessa Esquibel, Wendy Levin, ...> ;Cancer. 2015 Apr 1
71 citations
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
Johanna C. Bendell, Carla Kurkjian, Jeffrey R. Infante, Todd M. Bauer, Howard A. Burris, F. Anthony Greco, Kent C. Shih, D. S. Thompson, Cassie M. Lane, L Finney, Suza...> ;Investigational New Drugs. 2015 Feb 25
13 citations
Targeted enzyme prodrug therapy for metastatic prostate cancer - A comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase
Katrin P. Guillen, Carla Kurkjian, Roger G. Harrison> ;Journal of Biomedical Science. 2014 Jul 22
46 citations
A Phase I Dose Escalation Study of Oral c-MET Inhibitor Tivantinib (ARQ 197) in Combination with Gemcitabine in Patients with Solid Tumors
Shubham Pant, Mansoor N. Saleh, Johanna C. Bendell, Jeffrey R. Infante, Suzanne F. Jones, Carla Kurkjian, Kathleen M. Moore, Julia Kazakin, Giovanni Abbadessa, Yulei W...> ;Annals of Oncology. 2014 Jul 1
8 citations
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
Shubham Pant, Howard A. Burris, Kathleen N. Moore, Johanna C. Bendell, Carla Kurkjian, Suzanne F. Jones, Ofir Moreno, John G. Kuhn, Scott McMeekin, Jeffrey R. Infante> ;Investigational New Drugs. 2014 Jan 1
Psycho-oncology: a brief history and case study.
Natalie Kurkjian, Carla Kurkjian, Shubham Pant, Phebe Tucker> ;The Journal of the Oklahoma State Medical Association. 2013 Dec 1
15 citations
Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature.
Brent D. Van Rite, John J. Krais, Mohamad Cherry, Vassilios I. Sikavitsas, Carla Kurkjian, Roger G. Harrison> ;Cancer Investigation. 2013 Oct 1
26 citations
Mitosis-targeting natural products for cancer prevention and therapy.
Chinthalapally V. Rao, Carla Kurkjian, Hiroshi Yamada> ;Current Drug Targets. 2012 Nov 30
Incidence and risk factors of cetuximab-induced hypersensitivity infusion reactions (HIRs).
Hopps S, Borders E, Medina P, Moorman M, Webb R, Kurkjian C, Pant S> ;J. Clin. Oncol.. 2011-05-20
Factors affecting resection rate in patients undergoing neoadjuvant therapy for pancreatic cancer.
Khawandanah M, Chimpiri R, Kurkjian C, Herman TS, Qubaiah OM, Postier R, Ghabach B, Thompson D, Pant S> ;J. Clin. Oncol.. 2011-05-20
2 citations
Advances in the Treatment of Metastatic Colorectal Cancer
Carla Kurkjian, Shivaani Kummar> ;Disease-a-Month. 2010 Apr 1
40 citations
Advances in the treatment of metastatic colorectal cancer.
Carla Kurkjian, Shivaani Kummar> ;American Journal of Therapeutics. 2009 Sep 1
58 citations
DNA Methylation: Its Role in Cancer Development and Therapy
Carla Kurkjian, Shivaani Kummar, Anthony J. Murgo> ;Current Problems in Cancer. 2008 Sep 1
3 citations
The observation that changes in DNA methylation potentially play a role in neoplastic transformation has existed for nearly 30 years. Foreword.
Carla Kurkjian, Shivaani Kummar, Anthony J. Murgo> ;Current Problems in Cancer. 2008 Sep 1
5 citations
Treatment of Recurrent Metastatic Colon Cancer in the Age of Modern Adjuvant Therapy
Carla Kurkjian, Anthony J. Murgo, Shivaani Kummar> ;Clinical Colorectal Cancer. 2008 Sep 1
3 citations
Cytogenetic changes associated with myelodysplastic syndrome affecting bone marrow engraftment analysis
Terence Dunn, Richard A. Allen, Francesca Bates, Carla Kurkjian, Rammurti T. Kamble, Mohamed A. Kharfan-Dabaja> ;The Journal of Molecular Diagnostics. 2006 May 1
8 citations
Acute promyelocytic leukemia and constitutional trisomy 21.
Carla Kurkjian, Sunil Patel, Rammurti T. Kamble, S. Terrence Dunn, William Kern, Mohamed A. Kharfan-Dabaja> ;Cancer Genetics and Cytogenetics. 2006 Mar 1
Join now to see all

Press Mentions

Former Volunteer Joins Mercy as Vice President of Cancer Services in OklahomaOctober 4th, 2016

Hospital Affiliations

OU Medical Center EdmondEdmond, Oklahoma
Mercy Hospital Fort SmithFort Smith, Arkansas
Mercy Hospital Oklahoma CityOklahoma City, Oklahoma

CarlaDKurkjianMD

Dr. Kurkjian is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.